Retatrutide vs Tirzepatide

Evidence-based comparison. Updated 2026.

Retatrutide and tirzepatide are both advanced incretin-based therapies, but retatrutide adds glucagon receptor activation to the GIP/GLP-1 dual mechanism, producing greater average weight loss in phase 3 trials. Tirzepatide is FDA-approved and clinically available, making it the practical choice today. Retatrutide may become preferable for those seeking maximal weight reduction once regulatory approval is achieved.

Side by side

	Retatrutide	Tirzepatide
Evidence	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved	AEvidenceGrade ALarge human randomised controlled trials, or FDA / major-authority approved
Regulatory	Phase 3 trialPhase 3 trialIn active large-scale human clinical trials, not yet approved	FDA approvedFDA approvedApproved by the US Food and Drug Administration for at least one use
Benefits	Exceptional weight loss (up to 24% body weight) Improves insulin sensitivity Reduces appetite significantly Improves metabolic health May preserve lean mass	Superior weight loss compared to semaglutide (average 20-25%) Effective diabetes management Improves insulin sensitivity Cardiovascular protection Reduces visceral fat
Dosage	0.5-12 mg mg, Once weekly	2.5-15 mg mg, Once weekly
Route	Subcutaneous	Subcutaneous
Category	Metabolic & Weight Loss	Metabolic & Weight Loss

Full research page

Retatrutide

Full research page

Tirzepatide

Which should you choose

Tirzepatide activates GIP and GLP-1 receptors, while retatrutide adds a third axis via glucagon receptor agonism. This additional mechanism increases energy expenditure and appears to drive meaningfully greater weight loss beyond what dual agonism alone achieves.

Choose Retatrutide when

Research subjects seeking the highest recorded average weight reduction, up to 24% body weight, observed in phase 3 trial data
Individuals whose primary goal is metabolic improvement, as glucagon receptor activation increases energy expenditure beyond appetite suppression alone
Those who have plateaued on dual GIP/GLP-1 agonists and are exploring next-generation triple-receptor options in a research context

Choose Tirzepatide when

Individuals who require an FDA-approved agent with established safety and dosing data across large clinical populations
People managing type 2 diabetes who need a compound with demonstrated glycaemic control and cardiovascular outcome data
Those who prefer a treatment with predictable availability, standardised formulations, and physician familiarity in clinical practice

Stacking retatrutide and tirzepatide is not a recognised research protocol, as both compounds act on overlapping GIP and GLP-1 receptors, which would risk additive gastrointestinal adverse effects without a clear mechanistic benefit.

Questions people ask

How does the weight loss magnitude of retatrutide compare to tirzepatide in head-to-head or parallel trial data?

No direct head-to-head randomised trial between retatrutide and tirzepatide has been published. Phase 3 data for tirzepatide shows average weight loss of roughly 20 to 22% in the SURMOUNT trials, while retatrutide phase 3 data indicates averages approaching 24% body weight reduction. These figures come from separate trials with different populations and designs, so direct comparison carries limitations.

Is there a meaningful difference in side effect profiles between retatrutide and tirzepatide?

Both compounds share a similar gastrointestinal side effect profile, including nausea, vomiting, diarrhoea, and constipation, which are common to incretin-based therapies. Retatrutide's glucagon receptor agonism may introduce a somewhat higher risk of nausea at escalating doses due to increased energy expenditure signalling. Tirzepatide's side effect profile is more thoroughly characterised given its larger and longer-running clinical database as an approved drug.

If someone is already using tirzepatide, is there a rationale for switching to retatrutide?

Switching could be considered in a research or clinical context if weight loss has plateaued on tirzepatide and additional reduction is a primary objective, given retatrutide's additional glucagon receptor activity. However, retatrutide is not yet commercially approved, so any such transition would currently occur outside standard clinical care. A treating physician would need to evaluate cardiometabolic goals, tolerance history, and individual risk factors before any protocol change.

Which peptide has stronger evidence supporting cardiovascular outcomes, retatrutide or tirzepatide?

Tirzepatide currently has stronger cardiovascular outcome evidence, supported by the SURPASS-CVOT trial data and its FDA approval for cardiovascular risk reduction in adults with obesity. Retatrutide has shown early cardiovascular biomarker improvements in phase 2 and phase 3 data, but dedicated large-scale cardiovascular outcome trials are still ongoing or incomplete. Until those results are published and reviewed, tirzepatide holds a more robust evidence base for cardiovascular endpoints.

Goal-based guides

Broader evidence guides for the goals this comparison relates to.

Best peptides for Fat Loss

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide